Sagimet Biosciences Inc. - Series A · NASDAQ:SGMT
Sagimet Biosciences Inc. - Series A — Sagimet Biosciences — Technical Presentation (March 2016)
21 slides from Sagimet Biosciences Inc. - Series A's technical presentation, March 2016

Slide 1: Preliminary Activity in the First in Human Study of TVB-2640
Preliminary Activity in the First in Human Study of the First-In- Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640 M. Patel1, A. Brenner2, J. Infante3, HT. Arkenau4, E. Borazanci5, G. Falchook6, J. Lopez7, S. Pant8, E. Dean9, P. Schmid10, M. O’Farrell11, H. Burris3 1Sarah Cannon Research Institu

Slide 2: Disclosure Slide
Disclosure Slide • Presenter: M. Patel – Disclosures: None 2

Slide 3: FASN – Integrated Target in Tumor Cell Biology
FASN – Integrated Target in Tumor Cell Biology Signaling Pathways - Receptor Localization & Activity Glucose Glutamine mitochondria Tumor cells are much citrate more dependent on Protein Modification & FASN than normal cells Acetyl-CoA Localization/Function Wnt RTK PI3K FASN p AKT Lipid mTOR palmita

Slide 4: TVB-2640 Oral, First-in-Class, Potent FASN Inhibitor
TVB-2640 Oral, First-in-Class, Potent FASN Inhibitor Potent, reversible, specific ( IC50 <0.05 μM), small molecule inhibitor (<440 MW) Inhibi(on of FASN kills Tumor Cells TVB-‐2640 Reduces Growth of COLO-‐205 Tumors in vivo (rat) Total Intracellular Palmitate TGI TGI% (%): 446 6% 58 58% 74 74% 150

Slide 5: Study Design and Objective
Study Design and Objective • Phase 1 Study – Oral, once daily; 21 days in monotherapy or 28 days with chemo; continuous cycles – Adult patients (ECOG 0-1), with pathologically confirmed metastatic or advanced-stage solid tumors, met accepted ph-1 In/Exclusion criteria – Clinically significant ophtha

Slide 6: Patient Baseline Characteristics
Patient Baseline Characteristics Monotherapy Combination Therapy N=53 Patients N=47 Patients Age Median 64 Age (years) Median 63 (years) Gender M/F 9:38 Gender M/F 21:32 ECOG 0 (19) 40% ECOG 0 (18) 34% 1 (28) 60% 1 (35) 66% * # of 0-2 (11) 25% * # of 0-2 (10) 19% Previous Previous Regimens 3-4 (17)

Slide 7: Expansion Cohorts Currently Enrolled
Expansion Cohorts Currently Enrolled Escalation Expansion NSCLC Monotherapy with CRC TVB-2640 • N=30 treated Monotherapy Exploratory: • 6 DLTs*: HCC (HCV+) • 3 Skin @ 120mg/m2 and Endometrial 240mg/m2 • 3 Eye @ 240mg/m2 and 250mg MTD declared at Liposarcoma 100mg/m2 Prostate / 11C-acetate monotherap

Slide 8: TVB-2640 Patient Plasma Levels
TVB-2640 Patient Plasma Levels Day 1 Day 8 100000" 100000" 10000" TVB$2640)(ng/ml)) 10000" TVB$2640)(ng/ml)) 1000" 1000" 60"mg/m2" 60"mg/m2" 100" 80"mg/m2" 100" 80"mg/m2" 120"mg/m2" 10" 10" 120"mg/m2" 240"mg/m2" 240"mg/m2" 1" 1" 0" 4" 8" 12" 16" 20" 24" 0" 4" 8" 12" 16" 20" 24" Time)(hr)) Time)(hr))

Slide 9: Monotherapy Gr 1/Gr 2/Gr 3 Related AEs
Monotherapy Gr 1/Gr 2/Gr 3 Related AEs Monotherapy Events Grade 1 Grade 2 Grade 3 N=53 AE Verbatim Any Gr 1/Gr 2 Related Adverse Event 48 (91%) Any ≥ Gr 3 Related Adverse Event 12 (22%) Skin and subcutaneous tissue 41 20 17 4 77% Gastrointestinal 26 21 5 - 49% Eye 26 15 8 3 49% General disorders and

Slide 10: Combotherapy Gr 1/Gr 2/Gr 3 Related AEs
Combotherapy Gr 1/Gr 2/Gr 3 Related AEs Combotherapy Events Grade 1 Grade 2 Grade 3 N=47 AE Verbatim Any Gr 1/Gr 2 Related Adverse Event 41 (87%) Any ≥ Gr 3 Related Adverse Event 11 (23%) Skin and subcutaneous tissue 32 14 13 5 68% Gastrointestinal 29 22 5 2 62% General disorders and administration

Slide 11: AE: Skin
AE: Skin • 120 mg/m2 • Gr. 2 Hand/Foot Skin Reaction • Onset on Cycle 3, Day 8 • Resolution 35 days later 11

Slide 12: AE: Ocular
AE: Ocular • 240 mg/m2 • DLT of Gr. 3 Corneal Edema • Onset on Cycle 2, Day 1 • Resolution 5 days later 12

Slide 13: Safety Summary
Safety Summary • DLTs (Eye tox, HFS) were reversible • At the MTD of 100mg/m2: On target expected adverse events -Eye toxicity: 100% AE’s were ≤ Grade 2 -Skin toxicity: 85% AE’s were ≤ Grade 2 • No added toxicities with TVB-2640 + Paclitaxel • No QTc prolongation has been seen • Mild GI toxicity 13

Slide 14: NSCLC weeks on study
NSCLC weeks on study Best Response KRAS SD MUT SD MUT SD MUT PD UNK PD UNK Monotherapy PD WT PD UNK PD UNK PD UNK SD MUT cPR (36%ê) MUT SD WT SD UNK SD UNK SD WT Combina(on PD UNK SD WT SD UNK SD UNK PD MUT PD UNK SD WT 14

Slide 15: Breast Weeks on Study
Breast Weeks on Study Best Response Taxane * SD D SD D SD -‐ cPR (67%ê) D SD P SD P SD P SD D cPR (47%ê) D SD D SD P + D SD P PR (32%ê) D SD tbd *P=Paclitaxel 15 D=Docetaxel

Slide 16: Ovarian Weeks on Study
Ovarian Weeks on Study Best Response CA-‐125 Drop Taxane * SD 98% P + P SD 78% P SD 76% P SD 58% P+P+P+P SD 74% P cPR (41%ê) 58% P SD -‐ P PD -‐ P PD -‐ P SD -‐ P PD -‐ P+P PD -‐ P *P=Paclitaxel 16 D=Docetaxel

Slide 17: TVB-2640 Inhibits FASN in Patients
TVB-2640 Inhibits FASN in Patients TVB-2640 • Mechanism related metabolites in serum change Acetyl-CoA FASN in line with preclinical data Palmitate in complex lipids Malonyl-CoA • Evidence of FASN engagement Malonyl Carnitine 4 1.2 p=0.0021 p<0.0001 Malonyl Carnitine 3 Tripalmitin 1.0 2 0.8 1 0 0.6

Slide 18: Activity in Patient Tumor Biopsies Demonstrated
Activity in Patient Tumor Biopsies Demonstrated Tumor – exploratory biomarkers Sebum -‐ lipogenesis • Gene expression in macro- • Novel non-invasive approach using dissected tumor by RNA-Seq sebutape on forehead • Significantly more genes altered in tumor than normal tissue Lipid Reduction at C1D8

Slide 19: Activity in Patient Tumor Biopsies Demonstrated
Activity in Patient Tumor Biopsies Demonstrated 4/9 patients with paired biopsies had decreased pAKT S473 after 1 cycle Pre Post Breast, PIK3CA mut. monotherapy 50% inhibition Triple negative breast Combination 45% inhibition Vulvar Combination 33% inhibition Rectal/Anus Squamous 30% Combination inh

Slide 20: Conclusions
Conclusions • Promising early signs of clinical activity have been seen in heavily pre-treated patients: – Four confirmed partial responses when combined with weekly paclitaxel. – Prolonged SD in both treatment arms. – Responses have been seen across multiple tumor types, including KRASmut NSCLC, ov

Slide 21: Thank You to the Patients and Their Families
TVB-2640 Oral, First-in-Class, Potent FASN Inhibitor Thank You to the Patients and Their Families 21
Source: company website
More decks from Sagimet Biosciences Inc. - Series A
Investor Presentation (November 2026)33 slides · Nov 12, 2026
Investor Presentation (October 2026)31 slides · Oct 22, 2026
Investor Presentation (September 2026)30 slides · September 2026
Corporate Update (August 2026)22 slides · Aug 11, 2026
Investor Presentation (July 2026)22 slides · Jul 21, 2026
Corporate Update (April 2026)22 slides · Apr 30, 2026